1-8 of 8
Shun Xin Wang Lin
Close
Save search
Sort by
Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Available to Purchase
Clinical Trials & Observations
Cyrille Touzeau, Amrita Y. Krishnan, Philippe Moreau, Aurore Perrot, Saad Z. Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K. Nooka, Thomas G. Martin, Lionel Karlin, Xavier Leleu, Nizar J. Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca I. Verona, Suzette Girgis, Xin Miao, Clarissa M. Uhlar, Katherine Chastain, Alfred L. Garfall
Journal: Blood
Blood (2024) 144 (23): 2375–2388.
https://doi.org/10.1182/blood.2023023616
Published: 2024
Includes: Supplemental data
Journal Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Free
Clinical Trials & Observations
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, Onsay Lau, Karl Calara-Nielsen, Cuc Davis, Jaymala Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Z. Usmani, Nizar J. Bahlis, Niels W. C. J. van de Donk, Raluca I. Verona
Journal: Blood
Blood (2024) 144 (6): 615–628.
https://doi.org/10.1182/blood.2023022823
Published: 2024
Includes: Supplemental data
Journal Articles

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Free
Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis
Journal: Blood
Blood (2022) 140 (Supplement 1): 7253–7254.
https://doi.org/10.1182/blood-2022-162856
Published: 2022
Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Free
Diana Cortes-Selva, Tineke Casneuf, Deeksha Vishwamitra, Sarah Stein, Tatiana Perova, Sheri Skerget, Elena Ramos, Laure van Steenbergen, Dries De Maeyer, Rengasamy Boominathan, Onsay Lau, Cuc Davis, Arnob Banerjee, Tara Stephenson, Clarissa M. Uhlar, Rachel Kobos, Jenna D. Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S. Wu, Philippe Moreau, Saad Usmani, Nizar Jacques Bahlis, Niels WCJ Van De Donk, Raluca Verona
Journal: Blood
Blood (2022) 140 (Supplement 1): 241–243.
https://doi.org/10.1182/blood-2022-162709
Published: 2022
Journal Articles

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Free
Xin Miao, Liviawati S. Wu, Shun Xin Wang Lin, Yan Xu, Yang Chen, Yuki Iwaki, Rachel Kobos, Tara Stephenson, Kristy Kemmerer, Clarissa M. Uhlar, Arnob Banerjee, Jenna D. Goldberg, Danielle Trancucci, Raluca Verona, Lixia Pei, Yaming Su, Daniele Ouellet, Alfred L. Garfall, Amrita Y. Krishnan, Saad Usmani, Suzette Girgis, Honghui Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 4382–4383.
https://doi.org/10.1182/blood-2022-162859
Published: 2022
Journal Articles

Subcutaneous Teclistamab in Combination with Daratumumab for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma: Results from a Phase 1b Multicohort Study

Free
Paula Rodriguez-Otero, Bhagirathbhai Dholaria, Elham Askari, Donna E. Reece, Niels W.C.J. van de Donk, Ajai Chari, Hartmut Goldschmidt, Amrita Y. Krishnan, Thomas Martin, Maria-Victoria Mateos, Daniel Morillo Giles, Cesar Rodriguez, Laura Rosinol, Jesús F. San-Miguel, Anna Sureda, Ralph Wäsch, Katja Weisel, Raluca I. Verona, Shun Xin Wang Lin, Thomas J. Prior, Brendan M. Weiss, Mark Wade, Jenna D. Goldberg, Albert Oriol, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 1647.
https://doi.org/10.1182/blood-2021-148723
Published: 2021
Journal Articles

Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma

Free
Ajai Chari, Parameswaran Hari, Nizar J. Bahlis, Maria-Victoria Mateos, Niels W.C.J. van de Donk, Bhagirathbhai Dholaria, Alfred L. Garfall, Hartmut Goldschmidt, K. Martin Kortuem, Amrita Y. Krishnan, Thomas Martin, Daniel Morillo Giles, Albert Oriol, Donna E. Reece, Cesar Rodriguez, Paula Rodriguez-Otero, Jesús F. San-Miguel, Saad Z. Usmani, Raluca I. Verona, Shun Xin Wang Lin, Thomas J. Prior, Mark Wade, Brendan M. Weiss, Jenna D. Goldberg, Elham Askari
Journal: Blood
Blood (2021) 138 (Supplement 1): 161.
https://doi.org/10.1182/blood-2021-148813
Published: 2021
Journal Articles

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Free
Suzette Girgis, PhD BPharm, MS, Shun Xin Wang Lin, PhD, Kodandaram Pillarisetti, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Shoba Shetty, PhD, Tara Stephenson, PhD, Brandi W. Hilder, PhD, Brett Hanna, Jennifer Smit, Homer Adams III, PhD, Yu-Nien (Tom) Sun, PhD, Jeffrey R. Infante, MD, Yusri A Elsayed, MD PhD, Amarnath Sharma, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-140565
Published: 2020